Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies
Αρχική World News FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent...
Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies